Seattle Genetics, Inc. · Bothell, WA United States ·(NASDAQ (GM): SGEN)
Company Description
View Seattle Genetics, Inc. Locations On A US Map
This link will open in a new window
This link will open in a new window Seattle Genetics is working on monoclonal antibodies (MAbs) to treat a variety of cancers and autoimmune diseases. It is developing MAbs potent enough to fight cancer on their own, as well as those used in combination with other drugs. One of its lead candidates, SGN-40, uses a genetically engineered antibody targeted to treat non-Hodgkin's lymphoma, multiple myeloma, and leukemia. Genentech holds SGN-40's worldwide marketing rights. Other candidates use antibodies to target antigens in solid tumors. The company's second technology, focused on antibody-drug conjugates (ADC), has been licensed by several drug makers -- including Bayer , CuraGen , MedImmune , and Progenics -- to develop new cancer therapies. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Key Seattle Genetics, Inc. Financials
| Company Type | Public - NASDAQ (GM): SGEN Single Location |
| Fiscal Year-End | December |
| 2008 Sales (mil.) | $35.2 |
| 2008 Employees | 261 |
Seattle Genetics, Inc. Executives
21 executives listed for Seattle Genetics, Inc.'s Bothell, WA location.
| Title | Name & Bio | Contact |
| Chairman, President, and CEO | Clay Siegall | Network |
| CFO | Todd Simpson | Network |
| Chief Business Officer | Eric Dobmeier | Network |
Competition
Top Seattle Genetics, Inc. Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!